{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(43)"],"submitter":["Farge D"],"pubmed_abstract":["<h4>Background</h4>Clinical guidelines recommend at least 3-months low molecular weight heparin (LMWH) treatment for established venous thromboembolism (VTE) in cancer patients. However, no study has analyzed the impact of 3-6 months of LMWH therapy on quality-of-life (QoL) in cancer patients.<h4>Results</h4>Among 400 cancer patients included at M0, 88.8% received long-term LMWH. Using a random-effects linear regression model with time as covariate, QoL scores in the MOS SF-36 (Global HRQoL, 1.3-fold per month [95% confidence interval (CI) 0.81-1.79], <i>p</i> < 0.0001) and EORTC QLQ-C30 (global health status/qol, 2.25-fold per month [95% CI 1.63-2.88]; <i>p</i> < 0.0001) questionnaires significantly improved over the 6-month study period in patients treated with LMWH, while VEINES-QOL sco"],"journal":["Oncotarget"],"pagination":["26990-26999"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6007467"],"repository":["biostudies-literature"],"pubmed_title":["Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC)."],"pmcid":["PMC6007467"],"pubmed_authors":["Cajfinger F","Connors JM","Farge D","Vedrine L","Bensaoula O","Coudurier M","Rafii H","Benzidia I","Pere-Verge D","Berremili T","Bensalha H","Bonnet I","Li V","Falvo N","Couturaud F","Resche-Rigon M"],"additional_accession":[]},"is_claimable":false,"name":"Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC).","description":"<h4>Background</h4>Clinical guidelines recommend at least 3-months low molecular weight heparin (LMWH) treatment for established venous thromboembolism (VTE) in cancer patients. However, no study has analyzed the impact of 3-6 months of LMWH therapy on quality-of-life (QoL) in cancer patients.<h4>Results</h4>Among 400 cancer patients included at M0, 88.8% received long-term LMWH. Using a random-effects linear regression model with time as covariate, QoL scores in the MOS SF-36 (Global HRQoL, 1.3-fold per month [95% confidence interval (CI) 0.81-1.79], <i>p</i> < 0.0001) and EORTC QLQ-C30 (global health status/qol, 2.25-fold per month [95% CI 1.63-2.88]; <i>p</i> < 0.0001) questionnaires significantly improved over the 6-month study period in patients treated with LMWH, while VEINES-QOL sco","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2025-04-21T19:23:44.416Z","creation":"2019-03-26T23:42:46Z"},"accession":"S-EPMC6007467","cross_references":{"pubmed":["29930745"],"doi":["10.18632/oncotarget.25454"]}}